Compositions and methods for screening and identifying clinically aggressive prostate cancer
The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
1. A method of measuring the expression level of ZFP36 and PTEN in a subject having prostate cancer, the method consisting of:
a. measuring the binding of a first probe in a first sample from the subject, wherein the first probe specifically hybridizes to a nucleic acid having the sequence set forth in SEQ ID NO: 2, thereby measuring expression of ZFP36 in the subject, and
b. measuring the binding of a second probe in a second sample from the subject, wherein the second probe specifically hybridizes to a nucleic acid having the sequence set forth in SEQ ID NO: 15, 16, or 17, thereby measuring expression of PTEN in the subject.
2. The method of claim 1 , wherein the prostate cancer is a primary prostate tumor or a metastatic prostate cancer.
3. The method of claim 1 , wherein the subject is a human.
4. The method of claim 1 , wherein the sample is from a tumor lesion or comprises circulating tumor cells.
5. The method of claim 1 , wherein the first and second sample are the same sample.
6. The method of claim 1 , wherein the expression levels of ZFP36 and PTEN are mRNA levels.
7. A method of treating prostate cancer in a subject, comprising:
a) providing a biological sample from the subject,
b) measuring the expression level of a set of biomarkers consisting of ZFP36 and PTEN in the sample,
c) detecting decreased expression levels of the set of biomarkers consisting of ZFP36 and PTEN in the sample as compared to the expression level of ZFP36 and PTEN in control subjects without prostate cancer recurrence, and
d) treating the subject from step c) with one or more therapies selected from surgical castration, androgen deprivation therapy, a radiation therapy, an ablation therapy, a chemotherapy, a targeted therapy, or an immunotherapy.
8. The method of claim 7 , wherein the prostate cancer is a primary prostate tumor or a metastatic prostate cancer.
9. The method of claim 7 , wherein the subject is a human.
10. The method of claim 7 , wherein the sample is from a tumor lesion or comprises circulating tumor cells.
11. The method of claim 7 , wherein the sample for measuring the expression level of ZFP36 and sample for measuring the expression level of PTEN are the same sample.
12. The method of claim 7 , wherein the expression levels of ZFP36 and PTEN are mRNA levels.